Vaginal Estrogen Therapy for Patients with Breast Cancer.
On account of the good prognosis for patients with breast cancer, improving or maintaining the quality of life in the aftercare period is becoming more and more important. In particular, the increasing usage of aromatase inhibitors in the past few years has led to an increased incidence of vaginal atrophy with symptoms such as vaginal dryness, petechial bleeding, dyspareunia and recurrent cystitis. And just these symptoms have a detrimental impact on the quality of life of breast cancer patients. Application of a topical estrogen therapy represents the most effective means to treat vaginal atrophy. The use of a systemic or, respectively, topical hormone therapy is, however, contraindicated for breast cancer patients. Further clinical trials are needed in order to assess the safety of vaginal estrogen therapy.
University Medical Center Regensburg, Department of Gynecology and Obstetrics, Regensburg.
M
M
Moegele
University Medical Center Regensburg, Department of Gynecology and Obstetrics, Regensburg.
S
S
Buchholz
University Medical Center Regensburg, Department of Gynecology and Obstetrics, Regensburg.
S
S
Seitz
University Medical Center Regensburg, Department of Gynecology and Obstetrics, Regensburg.
C
C
Lattrich
University Medical Center Regensburg, Department of Gynecology and Obstetrics, Regensburg.
O
O
Ortmann
breast cancer; hormone therapy; quality of life; vaginal atrophy